Navigation Links
The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
Date:9/6/2007

Free, Interactive Workshop Features CML Expert, Jorge Cortes, M.D.

WHITE PLAINS, N.Y., Sept. 6 /PRNewswire/ -- Jorge Cortes, M.D., an expert on leukemia, will discuss novel treatment approaches for chronic myelogenous leukemia (CML) in a free telephone workshop entitled CML: A Model in Cancer Therapy. The program is scheduled for Thursday, Sept. 20, 2007, 12:00 p.m. - 1:00 p.m. ET.

The program is being offered by The Leukemia & Lymphoma Society, the leading source of information and support for patients battling leukemia, lymphoma and myeloma, and is supported by an unrestricted educational grant from Novartis.

Dr. Cortes is the deputy chair for the department of leukemia and professor of medicine and internist at The University of Texas M.D. Anderson Cancer Center in Houston, TX. His presentation will address the latest treatment options, emerging therapies, the role of clinical trials and quality of life considerations. A question-and-answer period will follow.

"Dr. Cortes will discuss the promising advances in CML treatment, and provide guidance on the importance of monitoring CML treatment and progress," says Robin Kornhaber, M.S.W., The Leukemia & Lymphoma Society's senior vice president of patient services.

The program is approved for 1.0 Continuing Education Unit for nurses and social workers upon verification of completion.

Registration

Registrants will receive an information packet and toll-free dial-in number within 48 hours of signing up. Participants can register online through http://www.lls.org/cmllinks or by phone at (866) 992-9950 ext. 302.

About Chronic Myelogenous Leukemia

CML is called by several names, including chronic granulocytic, chronic myelocytic or chronic myeloid leukemia. CML results from a change to the DNA of a stem cell in the marrow. Scientists do not yet understand what produces this change in the DNA, which is not present at birth.

The stem cell's changed DNA gives the malignant (cancerous) cell a growth and survival advantage over a normal stem cell. The resulting uncontrolled growth of white cells, if left untreated, will lead to a massive increase in their concentration in the blood. CML does not completely interfere with the development of mature red cells, white cells and platelets; these cells can generally continue to function normally. This is an important distinction from acute leukemia and accounts for the less severe early course of chronic leukemias.

About 4,570 people in the United States will learn they have CML in 2007 in the United States. About 21,501 people in the United States are living with CML. There will be an estimated 490 deaths from CML this year.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 5.1 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call the Society's Information Resource Center (IRC), a call center staffed by master's level oncology social workers and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

CONTACT: Andrea Greif

(914) 821-8958


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. GLEEVEC - An Oral treatment for leukemia
2. GLEEVEC - An Oral treatment for leukemia
3. Cyclosporin A Treats Leukemia Complications
4. Aspirin Lowers Leukemia Risk
5. Skin Allergies Found To Increase The Risk Of Leukemia
6. Night Light Found To Increase The Risk Of Leukemia
7. Treating Leukemia With Natural Cells
8. Exposure to EMF may cause leukemia
9. A new vaccine for leukemia
10. Leukemia pill shows promise against stomach cancer
11. Hope for Chemo-Resistant Leukemia Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... N.J. (PRWEB) , ... June 27, 2016 , ... Quality ... sources, yet in many ways they remain in the eye of the beholder, according ... (EBO), a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
Breaking Medicine Technology: